A Study to Assess the Effect of Hepatic Impairment on Safinamide Pharmacokinetics
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to investigate the pharmacokinetics (behavior of the
compound in the body) of safinamide in patients with different degrees of hepatic (liver)
impairment in comparison to matched subjects with normal hepatic function.